Abbott receives ce mark approval for next-generation triclip™ device, offering new innovations for tricuspid heart valve repair

Abbott park, ill., april 8, 2021 /prnewswire/ -- abbott (nyse: abt) today announced it has received ce mark for its next-generation triclip™ transcatheter tricuspid valve repair system, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in europe to treat tricuspid regurgitation (tr).
ABT Ratings Summary
ABT Quant Ranking